LCTX Lineage Bio Quick Ratio

The price action of Lineage Cell Therapeutics (LCTX) reflects market expectations for the developer of cellular therapies targeting injuries and vision loss. The business remains independent of economic cycles, relying instead on medical test results, with the indicator standing at 6.45. Investments carry risks associated with regulatory rejection and capital shortages, although the company is currently implementing AI-driven automation within its laboratories.

Lineage Bio (LCTX) Quick Liquidity: for the period 07/04/2022 - 10/29/2026

Summary analytical data breakdowns for lineagecell.com (LCTX)

- share price and expert price forecast:

Stock Price Lineage Bio|LCTX - Consensus Target

- market capitalization data:

Market Capitalization Lineage Bio|LCTX - Total Enterprise Value

- balance sheet net asset value indicators:

Net Assets per Single Share Lineage Cell Therapeutics|LCTX - Company Book Value|Market Value to Book Value Ratio lineagecell.com|LCTX - Aggregate Company Assets

- company liabilities and liquidity data:

- earnings and market multiples details:

LCTX - Company Net Income

Fundamental valuation:Lineage Bio - LCTX

Manufactured product of Lineage Cell Therapeutics, Inc.

The quick ratio measures a company's ability to meet short-term obligations using its most liquid assets, completely excluding illiquid inventories. High quick ratio values confirm financial stability and the absence of cash flow gap risks. For Lineage Cell Therapeutics (LCTX), this indicator is critically important, as regenerative medicine requires massive expenditures for the development of cellular technologies. Maintaining a sufficient volume of liquid funds guarantees the continuity of innovations in the treatment of blindness and spinal cord injuries.

Competitors of Lineage Cell Therapeutics (LCTX)